亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 利福霉素鈉CAS:14897-39-3
利福霉素鈉CAS:14897-39-3
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 14897-39-3
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
利福霉素鈉
CAS:14897-39-3
中文同義詞: 力復霉素SV;利福霉素SV鈉;利福霉素鈉;(12Z,14E,24E)-(2S,16S,17S,18R,19R,20R,21S,22R,23S)-21-乙酰氧基-1,2-二氫-6,9,17,19-四羥基-23-甲氧基-2,4,12,16,18,20,22-七甲基-1,11-二氧-2,7-(十五碳環氧-1,11,13-三烯亞胺)苯并[2,1-b]呋喃-5-酚一鈉鹽
英文名稱: Rifamycin sodium salt
英文同義詞: RIFAMPICIN SV SODIUM;RIFAMYCIN SV-SODIUM;RIFAMYCIN SV SODIUM SALT;RIFAMYCIN SV SODIUM SALT HEXAHYDRATE;rifamycin sodium salt;Rifamycin SV Monosodium;RIFAMYCIN,MONOSODIUMSALT;Rifamycin SV hexahydrate sodium salt
分子式: C37H46NNaO12
分子量: 719.75
EINECS號: 238-965-7
標準:ep6
效價:900 u/mg
性狀;本品為紅色結晶性粉末,無臭,味微苦。
用途:為抗生素類藥。劑型主要是注射用藥。用于結核桿菌感染的疾病和重癥耐甲氧西林金黃色葡萄球菌、表面葡萄球菌以及難治軍團菌感染的聯合治療。
包裝:1kg/鋁箔袋
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31120  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |